Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma

Mei Ju Chen, Yen Cheng Chen, Ching Kuang Chou, Wen-Ming Hsu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and travoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Seventy-three (73) CACG patients with IOP > 19 mmHg after peripheral iridotomy and without previous antiglaucoma medication were consecutively recruited. CACG was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment with either latanoprost 0.005% or travoprost 0.004% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost groups was significantly reduced, when compared to the baseline IOP (from 21.3 ± 1.8 mmHg to 16.0 ± 2.3 mmHg and 21.7 ± 1.7 to 16.7 ± 2.2 mmHg; P < 0.001 for both). There was no significant difference in IOP reduction between the 2 treatment groups (P = 0.19). At 4 and 8 weeks, the IOP changes from the baseline were statistically significant at all time points for both drugs (all P < 0.001). Conclusions: Both latanoprost and travoprost significantly reduced IOP in our sample of CACG patients after peripheral iridotomy.

Original languageEnglish
Pages (from-to)449-454
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Volume22
Issue number6
DOIs
Publication statusPublished - Dec 1 2006
Externally publishedYes

Fingerprint

latanoprost
Angle Closure Glaucoma
Intraocular Pressure
Travoprost
Gonioscopy

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. / Chen, Mei Ju; Chen, Yen Cheng; Chou, Ching Kuang; Hsu, Wen-Ming.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 22, No. 6, 01.12.2006, p. 449-454.

Research output: Contribution to journalArticle

@article{38b50f42dbca46ceb1cd7866231c144b,
title = "Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma",
abstract = "Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and travoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Seventy-three (73) CACG patients with IOP > 19 mmHg after peripheral iridotomy and without previous antiglaucoma medication were consecutively recruited. CACG was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment with either latanoprost 0.005{\%} or travoprost 0.004{\%} in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost groups was significantly reduced, when compared to the baseline IOP (from 21.3 ± 1.8 mmHg to 16.0 ± 2.3 mmHg and 21.7 ± 1.7 to 16.7 ± 2.2 mmHg; P < 0.001 for both). There was no significant difference in IOP reduction between the 2 treatment groups (P = 0.19). At 4 and 8 weeks, the IOP changes from the baseline were statistically significant at all time points for both drugs (all P < 0.001). Conclusions: Both latanoprost and travoprost significantly reduced IOP in our sample of CACG patients after peripheral iridotomy.",
author = "Chen, {Mei Ju} and Chen, {Yen Cheng} and Chou, {Ching Kuang} and Wen-Ming Hsu",
year = "2006",
month = "12",
day = "1",
doi = "10.1089/jop.2006.22.449",
language = "English",
volume = "22",
pages = "449--454",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma

AU - Chen, Mei Ju

AU - Chen, Yen Cheng

AU - Chou, Ching Kuang

AU - Hsu, Wen-Ming

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and travoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Seventy-three (73) CACG patients with IOP > 19 mmHg after peripheral iridotomy and without previous antiglaucoma medication were consecutively recruited. CACG was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment with either latanoprost 0.005% or travoprost 0.004% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost groups was significantly reduced, when compared to the baseline IOP (from 21.3 ± 1.8 mmHg to 16.0 ± 2.3 mmHg and 21.7 ± 1.7 to 16.7 ± 2.2 mmHg; P < 0.001 for both). There was no significant difference in IOP reduction between the 2 treatment groups (P = 0.19). At 4 and 8 weeks, the IOP changes from the baseline were statistically significant at all time points for both drugs (all P < 0.001). Conclusions: Both latanoprost and travoprost significantly reduced IOP in our sample of CACG patients after peripheral iridotomy.

AB - Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and travoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Seventy-three (73) CACG patients with IOP > 19 mmHg after peripheral iridotomy and without previous antiglaucoma medication were consecutively recruited. CACG was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment with either latanoprost 0.005% or travoprost 0.004% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost groups was significantly reduced, when compared to the baseline IOP (from 21.3 ± 1.8 mmHg to 16.0 ± 2.3 mmHg and 21.7 ± 1.7 to 16.7 ± 2.2 mmHg; P < 0.001 for both). There was no significant difference in IOP reduction between the 2 treatment groups (P = 0.19). At 4 and 8 weeks, the IOP changes from the baseline were statistically significant at all time points for both drugs (all P < 0.001). Conclusions: Both latanoprost and travoprost significantly reduced IOP in our sample of CACG patients after peripheral iridotomy.

UR - http://www.scopus.com/inward/record.url?scp=33846234362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846234362&partnerID=8YFLogxK

U2 - 10.1089/jop.2006.22.449

DO - 10.1089/jop.2006.22.449

M3 - Article

C2 - 17238812

AN - SCOPUS:33846234362

VL - 22

SP - 449

EP - 454

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 6

ER -